Trial Profile
A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)
Status:
Discontinued
Phase of Trial:
Phase III/IV
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Tenecteplase (Primary) ; Heparin
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms ASSENT-4-PCI
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Apr 2022 This trial has been completed in Spain (Global end date: 22 April 2006).
- 02 Jul 2008 Status changed from suspended to discontinued, as reported by ClinicalTrials.gov.
- 11 Nov 2005 New trial record.